Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer—significant effect of food intake on the bioavailability of the oral camptothecin analogue

This publication has 12 references indexed in Scilit:

• In vitro antitumor activity of 9-nitro-camptothecin as a single agent and in combination with other antitumor drugs.
  Annals of the New York Academy of Sciences, 2006
• Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
  New England Journal of Medicine, 2000
• Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
  The Lancet, 1998
• A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor
  Anti-Cancer Drugs, 1998
• Topotecan in colorectal cancer: A phase II study of the EORTC early clinical trials group
  Annals of Oncology, 1995
• Conversion of 9‐nitro‐camptothecin to 9‐amino‐camptothecin by human blood cells in vitro
  European Journal of Haematology, 1994
• 9-nitro-camptothecin delays growth of U-937 leukemia tumors in nude mice and is cytotoxic or cytostatic for human myelomonocytic leukemia lines in vitro
  European Journal of Haematology, 1993
• Review of methods and criteria for the evaluation of bioequivalence studies
  European Journal of Clinical Pharmacology, 1990
• Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata^1,2
  Journal of the American Chemical Society, 1966
• The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent
  Journal of Chronic Diseases, 1961